

# Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behçet's disease: a prospective study

Halûk Demiroğlu, Şuayib Yalçın, Yahya Büyükaşık, Osman İlhami Özcebe, Semra Dündar

## Abstract

**Objective**—Changes in blood rheology, especially increased erythrocyte aggregation (EA) might play an important part in the development of arterial and venous thrombotic lesions. A prospective study was designed to evaluate EA in patients with Behçet's disease (BD) and to see if this parameter is predictive for the future development of vascular complications, such as deep vein thrombosis of various organ systems and uveitis.

**Methods**—EA was measured by a photometric Myrenne aggregometer in 38 patients with BD at the time of initial diagnosis and in 40 age and sex matched healthy controls (HC).

**Results**—During a median follow up period of 13.5 months, 13 patients developed vascular-ocular complications (eight deep vein thrombosis, nine uveitis, and four both deep vein thrombosis and uveitis). Patients were further divided into two groups: BD-a with mucocutaneous symptoms and arthritis only; BD-b with associated vascular-ocular complications. EA values at high shear rate (M) and at low shear rate (M1) were compared among the groups.

**Conclusion**—EA values at M and M1 were significantly higher in BD-b than BD-a and HC ( $p < 0.001$ ). These results suggest that determination of EA rates might be useful to identify subgroups who are likely candidates for developing vascular-ocular complications in BD and management of factors known to affect blood rheology might be beneficial.

(*Ann Rheum Dis* 1998;57:694-696)

Behçet's disease (BD) is a multisystem inflammatory disorder characterised by recurrent oral and genital ulceration, uveitis, skin lesions, thrombosis of deep veins, arterial occlusion and/or aneurysms, arthritis, and central nervous system involvement (CNS).<sup>1</sup> While BD runs an indolent course in some patients with mucocutaneous manifestations dominating the clinical picture, on the other side of the spectrum, serious vascular complications such as uveitis and vascular occlusive disease may lead to great morbidity and even mortality.<sup>2</sup> The exact cause of these vascular problems is not precisely known. Anticardiolipin antibodies and increased lipoprotein-a concentrations leading to a decreased fibrinolytic activity have been reported as causative factors for a thrombotic tendency in BD.<sup>3,4</sup> It is well known that changes in haemorheological factors, especially increased erythrocyte aggregation (EA) might play an important part in the development of vascular thrombotic lesions both in arterial and venous systems.<sup>5,6</sup> Vascular lesions are a characteristic feature of BD, however, there is no simple determinant in whom a serious vascular complication will develop during the course of the disease. We designed a prospective study to investigate if EA was increased in patients with BD and to show if increased EA had a predictive value for future vascular complications.

## Methods

### PATIENTS AND CONTROLS

Thirty eight patients with BD and 40 age and sex matched healthy controls (HC) were enrolled into the study. Diagnosis of BD was based on the criteria proposed by the International Study Group for Behçet's Disease.<sup>7</sup> BD patients were newly diagnosed and none of them had serious vascular complications such as uveitis, venous or arterial thrombosis of various systems and CNS disease at the time of enrolment. Table 1 shows the clinical and laboratory features of BD patients and HC. BD patients were taking colchicine daily and benzathine penicilline once every three weeks. When vascular thrombosis developed, we began short-term anticoagulation followed by dipyridamole. In the case of eye involvement, topical corticosteroids together with systemic corticosteroids were used until inflammation subsided; then interferon was begun.

BD patients were followed up for a median of 13.5 months (range 6-24). During the follow up period, 13 patients developed vascular-ocular problems; eight patients devel-

Departments of  
Haematology  
H Demiroğlu  
Y Büyükaşık  
O İ Özcebe  
S Dündar

and Medical Oncology  
Ş Yalçın

Hacettepe University  
Medical School,  
Ankara, Turkey

Correspondence to:  
Dr H Demiroğlu, Hoşdere  
Cad 80/19, Yukarı Ayrancı,  
06550, Ankara, Turkey.

Accepted for publication  
23 July 1998

Table 1 Characteristics and initial findings of BD patients and HC

	BD patients	HC	BD-a	BD-b
Age (y)				
median	27	28	28	24
range	21-39	20-40	22-39	21-35
Sex (M/F)	23/15	24/16	15/10	8/5
Oral aphthae (n)	38		25	13
Genital ulcers (n)	35		23	12
Skin lesions* (n)	33		21	12
Positive pathergy test (n)	24		16	8
Arthritis (n)	15		11	4
Packed cell volume (%)	43.4 (0.48)	43.9 (0.46)	43.5 (0.56)	43.16 (0.9)
Cholesterol (mg/dl)	185.8 (3.3)	187.4 (2.7)	186.8 (3.6)	183.9 (6.8)
Fibrinogen (mg/dl)	248.5 (5.1)	235.8 (4.8)	245 (6.3)	255.3 (9)
ESR (mm 1st h)	31 (3.2)		31.1 (3.8)	30.8 (6)
CRP (mg/dl)	1.22 (0.2)		1.23 (0.25)	1.18 (0.38)

\*Includes folliculitis, papulopustular and acneiform lesions and erythema nodosum. Data shown as numbers, percentages, and mean (SD).




Figure 1 EA values of each group at M and M1 (n = number of subjects in each group).

oped deep vein thrombosis of various organ systems, nine patients developed uveitis, and four patients developed both deep vein thrombosis and uveitis. We further divided patients into two groups according to these vascular-ocular complications: BD-a (n = 25) with mucocutaneous symptoms and arthritis only; BD-b (n = 13) with associated vascular-ocular complications (table 1).

#### LABORATORY STUDIES

EA was studied by a photometric rheoscope (Myrenne aggregometer), which measures EA in 20  $\mu$ l of fasting venous blood anticoagulated with EDTA. Measurements were made at packed cell volume adjusted to 45% by removing or adding autologous plasma, after shearing at 600/sec, at stasis (high shear rate, M) and at 3/sec (low shear rate, M1).<sup>8</sup> All other parameters (packed cell volume, cholesterol, fibrinogen, erythrocyte sedimentation rate (ESR), and C reactive protein (CRP)) were tested by routine methods.

#### STATISTICAL METHODS

Mann-Whitney U test, Kruskal-Wallis test, and analysis of variance were used for comparisons among BD-a, BD-b, and HC groups where appropriate. Multivariate analysis was performed by using a multiple regression model. All values are expressed as mean (SD). A value of  $p < 0.05$  was accepted as statistically significant.

#### Results

No difference was found among the study groups BD-a, BD-b and HC in terms of age, sex, packed cell volume, cholesterol, and fibrinogen values (table 1,  $p > 0.05$ ).

ESR values in BD-a and BD-b were similar as well ( $p > 0.05$ ). When we took into consideration the patients with arthritis, we saw that ESR value of these patients was 52.2 (3.4) and those without arthritis was 17.21 (1.23) ( $p < 0.001$ ). There was no correlation between ESR and EA values at M and M1. CRP values in BD-a and BD-b were similar, too ( $p > 0.05$ ). Likewise, CRP was higher in patients with arthritis than those without (2.55 (0.27) v 0.34 (0.04),  $p < 0.001$ ). There was no correlation between CRP and EA at M and M1, either.

At the time of initial diagnosis, EA values at M in BD-a, BD-b and HC were as follows: 2.2 (0.04), 2.7 (0.07), and 2.25 (0.03), respectively (fig 1). The difference was significantly higher in BD-b than BD-a and HC ( $p < 0.001$ ), whereas there was no statistically significant difference between BD-a and HC groups ( $p > 0.05$ ). EA values at M1 in BD-a, BD-b, and HC were as follows: 7.32 (0.07), 8 (0.17), and 7.33 (0.04), respectively. Although there was no statistically significant difference between BD-a and HC, M1 was significantly higher in BD-b than BD-a and HC ( $p < 0.001$ ). After the vascular-ocular attack, as patients were taking dipyridamole or interferon treatment, EA was reassessed as post-treatment M (post-M) and post-M1. In BD-a and BD-b patients, post-M values were as follows: 2.21 (0.06) and 2.55 (0.06), respectively, and post-M1 as: 7.26 (0.07) and 7.66 (0.16), respectively. Although post-M and post-M1 were significantly lower than M and M1, respectively, in BD-b ( $p < 0.01$ ), these values were still higher than M and M1 values of BD-a patients and HC ( $p < 0.05$ ).

In multivariate analysis for the determination of factors influencing EA rates at M and M1, only vascular-ocular involvement was found to be significant, whereas age, sex, packed cell volume, cholesterol, fibrinogen, ESR, and CRP values had no significant effects. To demonstrate the prognostic value of erythrocyte aggregability, we calculated the relative risk ratio. The relative risk of vascular-ocular attack in BD patients with an EA value higher than HC was 12 for M and 5.5 for M1.

#### Discussion

BD is highly variable in its presentation and clinical course and there exists a marked individual variability.<sup>9</sup> Not all patients with BD suffer from severe complications. It is difficult to estimate at the time of diagnosis in whom the disease will run an aggressive clinical course. Some studies investigating the role of demographic features on the prognosis of BD showed that male sex and a younger age of onset (25 years or less) were associated with more severe forms of the disease with vascular, ocular or CNS manifestations.<sup>10 11</sup> However, there is no simple objective test to predict the prognosis of the disease at the time of diagnosis.

Haemorheological factors have long been implicated in the pathogenesis of vascular lesions in some diseases, such as diabetes mellitus and atherosclerotic heart disease.<sup>5 6 12</sup> Blood rheology is complex and EA is one of the important haemorheological properties that may create problems at the level of microcirculation. An increase in EA local blood flow and shear rate decrease cause local acidosis and an increase in platelet aggregation that lead to endothelial cell damage.<sup>5 6</sup> With this point of view we studied EA rate in BD to see if it was increased especially in patients with major complications, such as vascular occlusive disease and uveitis. We found that as in the angio-pathic forms of diabetic patients,<sup>12</sup> EA was increased in vascular complications of BD and

might be an independent risk factor for an aggressive clinical course. The causative factors for increased EA may be both intrinsic and extrinsic to the erythrocytes. In atherosclerotic diseases, red cell membrane lipid spectrum might change and this may lead to a change in dynamic properties of the red cell membrane. However, we could not find higher cholesterol concentrations in BD patients. It has long been known that fibrinogen causes formation of rouleaux of erythrocytes.<sup>13</sup> Each fibrinogen molecule is adsorbed onto the surface of the membrane of adjacent erythrocytes to bridge them, resulting in the formation of erythrocyte aggregates. Fibrinogen also increases blood viscosity, which has a negative effect on blood fluidity. Although we found higher fibrinogen values in BD-b when compared with BD-a and HC groups, the difference was not significant and they were still in the normal range. Follow up fibrinogen concentrations remained within the normal range in all groups, so it is unlikely that this parameter contributed to higher EA rates. We could not find a definite reason for the increased EA and the exact cause remains to be determined. It is not unusual for EA to be increased in vascular thrombotic disorders without known risk factors.<sup>14</sup> During follow up, post-M and post-M1 were still higher than M and M1 in BD-a and HC groups ( $p < 0.05$ ). This might be interpreted as that these patients are still at risk of recurrent vascular-ocular attack.

In conclusion, we suggest that determination of EA is a simple test that can be applied to clinical practice and it might be useful to identify subgroups who are likely candidates for developing vascular complications in BD. Hence, management of factors known to affect blood rheology like stress, cigarette smoking, abnormal lipid profile, and so on, might be of benefit to lower the risk of vascular complications.<sup>15</sup> Pharmacological approach to

the increased EA is a subject of investigation in recent years.  $\beta$  Blockers, calcium channel blockers, and ticlopidine are only a few drugs shown to decrease a rise in EA.<sup>6</sup> However, further and large scale studies are required to elucidate the mechanism(s) of increased EA and its role in the pathogenesis of vascular complications in BD.

There was no financial support for this study.

- 1 Shimizu T, Erlich GE, Inaba G, Hayashi K. Behçet's disease (Behçet's syndrome). *Semin Arthritis Rheum* 1979;8:223-60.
- 2 Haim S. Pathogenesis of Behçet's disease. *Int J Dermatol* 1983;22:101-2.
- 3 al Dalaan AN, al Ballaa SR, al Janadi MA, Bohlega S, Bahabri S. Association of anti-cardiolipin antibodies with vascular thrombosis and neurological manifestation of Behçet's disease. *Clin Rheumatol* 1993;12:28-30.
- 4 Orem A, Değer O, Memiş O, Bahadır S, Ovalı E, Cimsit G. Lp(a) lipoprotein levels as a predictor of risk for thrombotic events in patients with Behçet's disease. *Ann Rheum Dis* 1995;54:726-9.
- 5 Demiroğlu H, Barışta İ, Dündar S. Erythrocyte aggregability in patients with coronary heart disease. *Clinical Hemorheology* 1996;16:313-17.
- 6 Demiroğlu H. The importance of erythrocyte aggregation in blood rheology: considerations on the pathophysiology of thrombotic disorders. *Blood* 1997;89:4236.
- 7 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. *Lancet* 1990;335:1078-80.
- 8 Rampling MW, Martin G. A comparison of the Myrenne erythrocyte aggregometer with older techniques for estimating erythrocyte aggregation. *Clinical Hemorheology* 1989;9:41-6.
- 9 O'Neill TW, Rigby AS, McHugh S. Regional differences in clinical manifestations of Behçet's disease. In: Wechsler B, Godeau P, eds. *Behçet's disease*. Amsterdam: Excerpta Medica International Congress Series 1037, 1993:159-63.
- 10 Yazıcı H, Pazarlı H, Barnes CG, Tüzün Y, Özyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behçet's disease. *N Engl J Med* 1990;322:281-5.
- 11 Demiroğlu H, Barışta İ, Dündar S. Risk factor assessment and prognosis of eye involvement in Behçet's disease in Turkey. *Ophthalmology* 1997;104:701-5.
- 12 Demiroğlu H, Gürlek A. Altered red blood cell rheology as a predisposing factor for diabetic nephropathy. *Nephron* 1998;79:121-2.
- 13 Evans EA, Brooks DE. Rheology of blood cells. In: Chien S, Dormandy J, Ernst E, Matrai A, eds. *Clinical hemorheology*. Dordrecht: Martinus Nijhoff Publishers, 1987:73-96.
- 14 Glacet-Bernard A, Chabanel A, Lelong F, Samama MM, Coscas G. Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors. *Ophthalmology* 1994;101:1483-8.
- 15 Ernst E, Wehmayer T, Schmid M, Baumann M, Matrai A. Cardiovascular risk factors and hemorheology - physical fitness, stress and obesity. *Atherosclerosis* 1986;59:263-9.



## Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behçet's disease: a prospective study

Halûk Demiroglu, Suayib Yalçın, Yahya Büyükasik, Osman I?lhami Özcebe and Semra Dündar

*Ann Rheum Dis* 1998 57: 694-696  
doi: 10.1136/ard.57.11.694

---

Updated information and services can be found at:  
<http://ard.bmj.com/content/57/11/694>

---

### References

*These include:*

This article cites 13 articles, 2 of which you can access for free at:  
<http://ard.bmj.com/content/57/11/694#BIBL>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Topic Collections

Articles on similar topics can be found in the following collections

[Ophthalmology](#) (128)  
[Degenerative joint disease](#) (4641)  
[Musculoskeletal syndromes](#) (4951)

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>